

**3SBIO INCORPORATED:  
RAKING IN \$HK4.17 BILLION IN JUST NINE DAYS !**

The flotation of 3SBIO Incorporated () (Code: 1530, Main Board, The Stock Exchange of Hongkong Ltd) sucked up about \$HK4.17 billion, net of expenses, from investors of the Hongkong Special Administrative Region (HKSAR) of the People's Republic of China (PRC) and International Investors, singled out by the Joint Bookrunners and the Joint Lead Managers.

On June 1, 2015, 3SBIO published and disseminated its Global Offering Prospectus, Offering 606.10 million, \$US0.00001-cent Shares at the Indicative Offer Price Per Share, ranging from a low of \$HK8.30 to a high of \$HK9.10.

On June 10, 2015, it was announced that the Offer Price Per Share had been struck at the highest Indicative Offer Price level: \$HK9.10 Per Share.

Management announced that the \$HK4.17 billion that is obtained would be applied to the requirements of the Company as follows:

- Approximately, 45 percent of the net proceeds, that is about \$HK1,876.50 million, *'to expand the Company's portfolio of pharmaceutical products in the Company's focused therapeutic areas through selective acquisitions. The Company is primarily interested in acquiring companies with mature product lines and first-to-market drugs, as well as companies with high innovation capabilities'*;
- Approximately, 15 percent of the net proceeds, that is about \$HK625.50 million, *'to strengthen the sales and marketing of the products'*;
- Approximately, 15 percent of the net proceeds, that is about \$HK625.50 million, *'to fund capital expenditure projects to increase the Company's production capabilities by constructing new production lines in anticipation of the expected increase in demand for the Company's current products and the launch of product candidates'*;
- Approximately, 15 percent of the net proceeds, that is about \$HK625.50 million, *'to fund the Company's research and development projects, including in-house research and development projects and external collaboration projects'*; and,
- Approximately, 10 percent of the net proceeds, that is about \$HK417.0 million, *'to supplement the Company's working capital and for general corporate purposes.'*

Of the total number of Shares on Offer, 484.88 million Shares were New Shares and 121.22 million Shares were those, belonging to the Selling Shareholder.

(The Selling Shareholder was CS Sunshine Investment Ltd, a company, incorporated in the **British Virgin Islands (BVI)**, and being beneficially owned by an independent third party.)

Investors of the HKSAR were Offered 60.61 million New Shares and this share tranche was oversubscribed by about 201.57 times.

As for the International Placing tranche of 545.49 million Shares, which included CS Sunshine's Sale Shares of 121.20 million Shares, along with 424.27 million New Shares, Management announced that the number of Shares, being requested by institutions and well-heeled, International Investors, had been '*significantly over-subscribed*'.

In ... [CLICK TO ORDER FULL ARTICLE](#)

***While TARGET makes every attempt to ensure accuracy of all data published,  
TARGET cannot be held responsible for any errors and/or omissions.***

*If readers feel that they would like to voice their opinions about that which they have read in **TARGET**, please feel free to e-mail your views to [editor@targetnewspapers.com](mailto:editor@targetnewspapers.com). **TARGET** does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.*